Corcept Therapeutics Shares Fall Again Amid Report FDA Warned Several Times Not to Submit Relacorilant Drug Application - Hagens Berman 30 January
Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer 22 January
Corcept Therapeutics Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman 06 January
